Tue. Aug 20th, 2019

My Health Reporter

Leading Health News Website

Hormone Biosimilars Market Global Share to Witness Comprehensive Growth By 2029

3 min read

Growth hormone deficiency causes when pituitary gland does not produce the desired amount of the growth hormones. There are various disorders related to lack of growth hormones in the adults as well as children. Growth hormone deficiency is rare disorder and it can be present from the birth, genetic mutations, trauma, exposure to certain radiations, infection and tumor growth inside the brain. The incidence of the growth hormone deficiency is reported to be around 1 in 7,000 in the U.S. The diagnosis plays major role in the management of growth hormone deficiency. Children with cleft palates are often result of growth hormone deficiency. The growth hormone deficiency may result in various deformities ranging from non-proportionate body organs to abnormal body functioning. Various psychological symptoms may occur such as depression, lack of concentration, poor memory and anxiety, etc. in patient with growth hormone deficiency.

Increasing early diagnosis of the growth hormone related disorder is the major driver in the growth of the growth hormone biosimilars market. The evolving methods of diagnosis of the growth hormone deficiency further expected to boost the diagnosis rate, driving the growth of growth hormone biosimilars market. The patent expiry of various growth hormone biologics in near future expected to generate significant revenue generation in regulated markets such as North America, Europe and Japan, fueling the growth of growth hormone biosimilars market. With patent expiry various manufacturers in the growth hormone biosimilars market are looking to expand it’s product offering across various countries driving the growth of growth hormone biosimilars market.

Request Sample For This Premium Report@ https://www.persistencemarketresearch.com/samples/29467

The manufacturers in the growth hormone biosimilars market are focusing on building strong pipeline with variety of molecules further expected to drive the growth of growth hormone biosimilars market. Due to low cost as compared to biologics, patients as well as healthcare professionals are preferring growth hormone biosimilars for the treatment. Whereas, tedious manufacturing process of the growth hormone biosimilars may hamper the potential revenue generation opportunity in the global growth hormone biosimilars market. Stringent regulatory rules for the approval process may also hamper the growth of the growth hormone biosimilars market.

The global growth hormone biosimilars market is segmented on the basis of indication, distribution channel and region.

On the basis of indication, the global growth hormone biosimilars market is segmented as:

  • Genetic Mutation Associated Growth Hormone Disorder
  • External Factors (such as trauma, infection, brain tumor, etc.) associated Growth Hormone Disorder
  • Others

On the basis of distribution channel, the global growth hormone biosimilars market is segmented as:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

The growth hormone biosimilars market is expected to experience steady growth over the forecast period due to increase number of patent expiry and creating opportunities for growth hormone biosimilars market players. By indication, genetic mutation associated growth hormone disorder expected to be the largest revenue generation segment in the global growth hormone biosimilars market. By distribution channel, retail pharmacies expected to be the highest revenue generating segment in the global growth hormone biosimilars market due to superior patient convenience.

Request TOC For This Premium Report@ https://www.persistencemarketresearch.com/toc/29467

North America is expected to be the highest revenue generating region in the global growth hormone biosimilars market owing to widespread product availability. Latin America is expected to experience steady growth in the global growth hormone biosimilars market due to increasing product availability in the region. Europe is expected to be the second most lucrative region in the global growth hormone biosimilars market due to higher diagnosis rate. Asia-Pacific is expected to be the fastest growing region in the global growth hormone biosimilars market due to increasing adoption of the available treatment options for the disorder. Middle East & Africa is expected to be the least revenue generating region in the global growth hormone biosimilars market.

Key participants operating in the global growth hormone biosimilars market are: Teva Pharmaceuticals, Novo Nordisk A/S, Novartis AG, Merck KGaA, Eli Lilly and Company, Theratechnologies Inc., F. Hoffmann-La Roche AG, among others.

Leave a Reply

Your email address will not be published. Required fields are marked *